Richard Brudnick

Richard Brudnick is a Venture Advisor at Israel Biotech Fund. Richard is also the Chief Business Officer at Codiak BioSciences. Prior to joining Codiak, Mr. Brudnick was EVP of Business Development and Alliance Management at Bioverativ, Inc., a company he helped found in 2016.

Prior to Bioverativ’s acquisition by Sanofi in March 2018, Mr. Brudnick successfully led business development efforts to build a significant pipeline in rare blood disorders including the acquisition of True North Therapeutics. Mr. Brudnick joined Bioverativ at its spin-off from Biogen where, over the course of nearly 15 years, he initiated, led, and completed transactions that now include many of the company’s marketed products and late-stage pipeline programs, including Tecfidera, Spinraza, its biosimilars joint venture with Samsung and its late-stage Alzheimer’s programs partnered with Eisai.

Mr. Brudnick also was CEO of a regional pharmaceutical distribution business, which he sold to a strategic buyer, co-founded two companies, and was a strategy consultant at Bain & Company.